Equity · Healthcare
KYTX
NASDAQKyverna Therapeutics (KYTX)
The line runs 4.88 USD on 6 November through 4.25 USD on 20 November, on a scale from 4.0 to 5.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 268.7M USD
- EPS, diluted, year to Dec 2025
- −3.64 USD
- 52-week range
- 4.25 USD – 12 USD
- Avg volume
- 172.7K
- Mentions, 30 days
- 2
as of Nov 20, 2026
Have Kyverna Therapeutics (KYTX) insiders bought or sold shares recently?
KYTX's newest Form 4 filing is dated 27 May 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Dec 2025 | SEIDENBERG BETH CDirector | Buy | 133,333 | 1.0M USD |
| 18 Dec 2025 | Westlake BioPartners Opportunity Fund I, L.P.10% Owner | Buy | 133,333 | 1.0M USD |
| 15 Dec 2025 | Walker Karen MarieChief Technology Officer | Sell | 23,998 | 293K USD |
| Bought | 2 open-market purchases | 266,666 | $2.00M | |
| Sold | 1 open-market sale | 23,998 | $293K |
12 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 27 May 2026 | CLARK IAN TDirector | Award | 5,093 | |
| 27 May 2026 | Cohen Fred EDirector | Award | 5,093 | |
| 27 May 2026 | SEIDENBERG BETH CDirector | Award | 5,093 | |
| 27 May 2026 | Shaw ChristiExecutive Chairperson | Tax withheld | 4,194 | 36K USD |
| 27 May 2026 | Aktar MertDirector | Award | 5,093 | |
| 13 Mar 2026 | GEHCHAN NAJISee Remarks | Award | 18,000 | |
| 13 Mar 2026 | GRASSO MARCChief Financial Officer | Award | 10,000 | |
| 13 Mar 2026 | Biddle Warner WestonChief Executive Officer | Award | 58,000 | |
| 24 Feb 2026 | Miller Andrew CraigDirector | Award | 11,006 | |
| 24 Feb 2026 | Emany Sravan KumarDirector | Award | 11,006 | |
| 12 Jan 2026 | Shaw ChristiExecutive Chairperson | Award | 54,301 | |
| 15 Dec 2025 | Walker Karen MarieChief Technology Officer | Option exercise | 23,998 | 116K USD |
Which funds hold Kyverna Therapeutics (KYTX)?
9 of the 45 institutional funds we track reported a Kyverna Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 826,137 | 5.6M USD | +29.1% |
| Renaissance Technologies | Held (±25%) | 327,821 | 2.2M USD | −1.8% |
| Point72 Asset Management | New position | 186,902 | 1.3M USD | |
| D. E. Shaw & Co. | Trimmed | 146,890 | 999K USD | −68.7% |
| Citadel Advisors | Held (±25%) | 137,034 | 932K USD | −7.2% |
| Marshall Wace | New position | 73,276 | 498K USD | |
| Man Group | Held (±25%) | 71,918 | 489K USD | +4.8% |
| Two Sigma Investments | Trimmed | 21,575 | 147K USD | −58.0% |
| AQR Capital Management | New position | 16,380 | 111K USD | |
| Balyasny Asset Management | Exited |
What has been filed or recorded for Kyverna Therapeutics (KYTX)?
The filings we hold for Kyverna Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 7,241 shares | 39K USD notional · 0.011% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,892 shares | 28K USD notional · 0.008% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,458 shares | 56K USD notional · 0.015% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,660 shares | 27K USD notional · 0.007% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,428 shares | 21K USD notional · 0.005% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.68 USD | |
| 30 Sep 2026 | Financials | Total assets | 189.4M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 133.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.63 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.66 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.64 USD | |
| 31 Dec 2025 | Financials | Net income | −161.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.64 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.85 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.97 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.03 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.33 USD |
What is Reddit saying about Kyverna Therapeutics (KYTX)?
Reddit mentioned KYTX 2 times in the 30 days to 21 November 2026, across 2 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Kyverna Therapeutics (KYTX) compare with its price?
Share ↗
Which subreddits are talking about Kyverna Therapeutics (KYTX)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 50% | 1 | +0.11 |
| r/stocks | 50% | 1 | +0.13 |
What do people ask about Kyverna Therapeutics (KYTX)?
What did Kyverna Therapeutics shares close at?4.25
Kyverna Therapeutics closed at 4.25 USD on 20 Nov 2026, down 2.97% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Kyverna Therapeutics’ market cap?268.7M
Kyverna Therapeutics is worth 268.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Kyverna Therapeutics insiders bought or sold shares recently?
No Kyverna Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 27 May 2026 (SEC Form 4). See Insiders
Which funds own Kyverna Therapeutics?9 of 45
9 of the 45 funds we track reported a Kyverna Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Renaissance Technologies and Point72 Asset Management. See Funds
When did Kyverna Therapeutics last report earnings?−0.68
Kyverna Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.68 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Kyverna Therapeutics?0 mentions
Kyverna Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words